Endometrial Neoplasms

Endometrial cancer literature in the grounding emphasizes molecular heterogeneity, including mismatch-repair and microsatellite instability status, which has therapeutic implications. It also highlights tumor biology involving signaling pathways, gene expression regulation, DNA integrity, growth factors, hormonal signaling, and metabolism. Tumor-infiltrating lymphocytes are discussed as part of the immune response with prognostic and predictive relevance.

Management is described at the level of surgery, radiotherapy, and systemic therapy for endometrial carcinoma, with updated multidisciplinary guidelines from ESGO/ESTRO/ESP. Systemic treatment in the grounding includes platinum-based chemotherapy such as carboplatin and paclitaxel, immune checkpoint inhibitors such as dostarlimab and pembrolizumab, and antibody-drug conjugates in selected settings. The literature also notes targeted approaches directed at signaling pathways and HER2 in endometrial cancer.